{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Participants+Study&page=2",
    "query": {
      "condition": "Healthy Participants Study",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Participants+Study&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:53:38.236Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05395117",
      "title": "A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD5462",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2022-06-30",
      "completion_date": "2022-09-12",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05395117"
    },
    {
      "nct_id": "NCT05226923",
      "title": "Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "KSP-1007",
          "type": "DRUG"
        },
        {
          "name": "Placebo:0.9% sodium chloride",
          "type": "OTHER"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sumitovant Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 123,
      "start_date": "2022-01-12",
      "completion_date": "2022-10-01",
      "has_results": false,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05226923"
    },
    {
      "nct_id": "NCT00835588",
      "title": "Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Pantoprazole Sodium 40 mg delayed-release tablets",
          "type": "DRUG"
        },
        {
          "name": "PROTONIX® 40 mg delayed-release tablets.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2003-12",
      "completion_date": "2003-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 2,
      "location_summary": "Saint Charles, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00835588"
    },
    {
      "nct_id": "NCT03363815",
      "title": "A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heathy Volunteer"
      ],
      "interventions": [
        {
          "name": "CC-90001",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 56,
      "start_date": "2017-12-04",
      "completion_date": "2018-07-29",
      "has_results": false,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363815"
    },
    {
      "nct_id": "NCT00942240",
      "title": "Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ACU-4429",
          "type": "DRUG"
        },
        {
          "name": "matching placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kubota Vision Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-07",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2012-01-10",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942240"
    },
    {
      "nct_id": "NCT00580190",
      "title": "Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "PF-00572778",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2007-09",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2009-09-14",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580190"
    },
    {
      "nct_id": "NCT00075296",
      "title": "FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 100,
      "start_date": "2004-01-05",
      "completion_date": "2008-04-21",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00075296"
    },
    {
      "nct_id": "NCT00541996",
      "title": "Study Comparing Bioavailability of Oral Formulations of Vabicaserin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "vabicaserin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": null,
      "start_date": "2007-08",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00541996"
    },
    {
      "nct_id": "NCT04480333",
      "title": "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome (SARS) Pneumonia",
        "Severe Acute Respiratory Syndrome of Upper Respiratory Tract",
        "Neurodegeneration",
        "Neuroinflammatory Response"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831 - 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: NA-831 - 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.10 mg + 1.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.20 mg + 2.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-15",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Sunnyvale, California",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480333"
    },
    {
      "nct_id": "NCT02089048",
      "title": "Auranofin PK Following Oral Dose Administration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amoebiasis"
      ],
      "interventions": [
        {
          "name": "Auranofin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-04-02",
      "completion_date": "2015-05-13",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-06-11T04:53:38.236Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02089048"
    }
  ]
}